Resources

×

  • Oncology

Market Access Downloads

Acute Myeloid Leukemia

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Messaging Playbooks

Monitor Payer Messaging Perception: Oncology...

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in oncology biosimilars.

Messaging Playbooks

Monitor Payer Messaging Perception: Non-Small...

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in non-small cell lung cancer.

Messaging Playbooks

Monitor Payer Messaging Perception: Breast...

In addition to outlining five ways to optimize your message strategy and drive sales, this playbook also includes real messages and payer reactions in breast cancer.

Market Access Downloads

Non-Small Cell Lung Cancer

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Indication Brief Excerpts

Metastatic Melanoma

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Non-Small Cell Lung Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Bladder Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Breast Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Market Access Downloads

Prostate Cancer

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Market Access Downloads

Multiple Myeloma

MMIT’s Market Access Downloads combine payer perceptions from Message Monitor and coverage data from Analytics.

Webinars

Meet the Expert: Pathways Utilization...

Learn how a product’s placement on pathways affects its utilization and uptake, and ultimately, patient’s access to life saving therapies.

Indication Brief Excerpts

Colorectal Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Multiple Myeloma

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Indication Brief Excerpts

Prostate Cancer

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

P&T Sessions

Neutropenia

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

Financial considerations for Rolontis® (Contracting...

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

What shifts have been observed...

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

Does Neulasta® Onpro® retain any...

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

Oncologist reactions to Rolontis®. Is...

MMIT’s P&T Persectives on Neutropenia reviewed Rolontis® (eflapegrastim), a new long-acting rhG-CSF therapy for patients with chemotherapy induced neutropenia.

P&T Sessions

Non-Small Cell Lung Cancer

Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Is there a product that...

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Introduction into scenario 1 pricing

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Oncologist’s opinion on the drugs...

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

P&T Sessions

Question posed by non-Oncologist P&T...

P&T Session NSCLC: Syndicated IDN P&T session focused on the entry of two new medications; capmatinib (Tabrecta) from Novartis, and tepotinib from Merck. Indicated for the treatment of adult patients with METex14 skipping mutation NSCLC.

Indication Brief Excerpts

CAR-T

This excerpt gives a sneak preview of the report, which combines in-depth narratives with data-rich charts to provide current insights about a single indication, sourced from the industry-leading Biologics and Oncology Indices.

Title

Description